Redox-responsive degradable prodrug nanogels for intracellular drug delivery by crosslinking of amine-functionalized poly(N-vinylpyrrolidone) copolymers.


Journal

Journal of colloid and interface science
ISSN: 1095-7103
Titre abrégé: J Colloid Interface Sci
Pays: United States
ID NLM: 0043125

Informations de publication

Date de publication:
22 Mar 2019
Historique:
received: 21 11 2018
revised: 09 01 2019
accepted: 11 01 2019
pubmed: 29 1 2019
medline: 23 7 2019
entrez: 29 1 2019
Statut: ppublish

Résumé

Facile approaches for the development of new tailored drug carriers are of high importance for the controlled administration of drugs. Herein we report a method for the synthesis of water-soluble reactive copolymers with well-defined architectures for fabrication of redox-sensitive degradable prodrug nanogels for intracellular drug release. Primary amine-functionalized statistical copolymers were obtained by hydrolysis of poly(N-vinylpyrrolidone-co-N-vinylformamide) copolymers which were synthesized via Reversible Addition-Fragmentation chain-Transfer (RAFT) polymerization. Redox-sensitive degradable nanogels with varying crosslinking densities were synthesized with a redox-sensitive cross-linker. Doxorubicin (DOX) was loaded to form prodrug nanogels (DNG) with hydrodynamic radius from 142 nm to 240 nm. The nanogels demonstrated slower degradation and retarded drug release rate with increased crosslinking density in the presence of 10 mM reduced glutathione (GSH) at 37 °C. The in vitro release studies revealed that maximum 85% DOX was released in 24 h under a reductive environment. Intracellular drug release profiles in HeLa cells indicated that the DOX delivery rate was tunable via varying crosslinking density of the nanogels. Cell viability assay demonstrated that the blank nanogels were biocompatible in wide concentrations up to 0.5 mg/mL while the DOX-loaded nanogels displayed medium antitumor activity with IC50 (half-maximal inhibitory concentration) of 1.80 μg/mL, 2.57 μg/mL, 3.01 μg/mL for DNG5, DNG10 and DNG15 respectively.

Identifiants

pubmed: 30690386
pii: S0021-9797(19)30061-X
doi: 10.1016/j.jcis.2019.01.049
pii:
doi:

Substances chimiques

Antibiotics, Antineoplastic 0
Cross-Linking Reagents 0
Delayed-Action Preparations 0
Gels 0
Doxorubicin 80168379AG

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

612-622

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Huan Peng (H)

Functional and Interactive Polymers, Institute of Technical and Macromolecular Chemistry, RWTH Aachen University, Forckenbeckstraße 50, D-52074 Aachen, Germany; DWI-Leibniz Institute for Interactive Materials e.V., Forckenbeckstraße 50, D-52074 Aachen, Germany.

Xiaobin Huang (X)

Developmental BioEngineering, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500 AE, the Netherlands.

Andrea Melle (A)

Functional and Interactive Polymers, Institute of Technical and Macromolecular Chemistry, RWTH Aachen University, Forckenbeckstraße 50, D-52074 Aachen, Germany; DWI-Leibniz Institute for Interactive Materials e.V., Forckenbeckstraße 50, D-52074 Aachen, Germany.

Marcel Karperien (M)

Developmental BioEngineering, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500 AE, the Netherlands.

Andrij Pich (A)

Functional and Interactive Polymers, Institute of Technical and Macromolecular Chemistry, RWTH Aachen University, Forckenbeckstraße 50, D-52074 Aachen, Germany; DWI-Leibniz Institute for Interactive Materials e.V., Forckenbeckstraße 50, D-52074 Aachen, Germany. Electronic address: pich@dwi.rwth-aachen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH